Migard (frovatriptan) is a new drug on the Danish market. Frovatriptan belongs to the group of triptans, which beforehand contains 6 other triptans: almotriptan, eletriptan, naratriptan, sumatriptan, rizatriptan og zolmitriptan. The indication is like the other triptans, acute treatment of the headache phase of migraine with or without aura.
Frovatriptan 2,5 mg is after 2 and 4 hours found to be a little less effective compared to sumatriptan 100 mg, but frovatriptan has longer half-life. Therefore, it is assumed, that frovantriptan is appropriate in treatment of long-term migraine attack. In addition frovatriptan has fewer side effects than sumatriptan.
The price should be the decisive choice when choosing treatment with triptanes. In the moment frovatriptan is the cheapest triptan on the market except for generic sumatriptan, (note the pricelist in the Danish version.
Frovatriptan was marketed 24 September 2007 in 2,5 mg tablets.